Copyright Reports & Markets. All rights reserved.

Global Companion Cancer Diagnostics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered: Ranking by Companion Cancer Diagnostics Revenue
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
      • 1.4.2 Breast Cancer
      • 1.4.3 Lung Cancer
      • 1.4.4 Colorectal Cancer
      • 1.4.5 Melanoma
      • 1.4.6 Gastric Cancer
    • 1.5 Market by Application
      • 1.5.1 Global Companion Cancer Diagnostics Market Share by Application: 2020 VS 2026
      • 1.5.2 Pharmaceutical & Biopharmaceutical Companies
      • 1.5.3 Reference Laboratories
      • 1.5.4 CROs
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends by Regions

    • 2.1 Companion Cancer Diagnostics Market Perspective (2015-2026)
    • 2.2 Companion Cancer Diagnostics Growth Trends by Regions
      • 2.2.1 Companion Cancer Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
      • 2.2.2 Companion Cancer Diagnostics Historic Market Share by Regions (2015-2020)
      • 2.2.3 Companion Cancer Diagnostics Forecasted Market Size by Regions (2021-2026)
    • 2.3 Industry Trends and Growth Strategy
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis
      • 2.3.5 Companion Cancer Diagnostics Market Growth Strategy
      • 2.3.6 Primary Interviews with Key Companion Cancer Diagnostics Players (Opinion Leaders)

    3 Competition Landscape by Key Players

    • 3.1 Global Top Companion Cancer Diagnostics Players by Market Size
      • 3.1.1 Global Top Companion Cancer Diagnostics Players by Revenue (2015-2020)
      • 3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2015-2020)
      • 3.1.3 Global Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.2 Global Companion Cancer Diagnostics Market Concentration Ratio
      • 3.2.1 Global Companion Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
      • 3.2.2 Global Top 10 and Top 5 Companies by Companion Cancer Diagnostics Revenue in 2019
    • 3.3 Companion Cancer Diagnostics Key Players Head office and Area Served
    • 3.4 Key Players Companion Cancer Diagnostics Product Solution and Service
    • 3.5 Date of Enter into Companion Cancer Diagnostics Market
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2015-2026)

    • 4.1 Global Companion Cancer Diagnostics Historic Market Size by Type (2015-2020)
    • 4.2 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2021-2026)

    5 Companion Cancer Diagnostics Breakdown Data by Application (2015-2026)

    • 5.1 Global Companion Cancer Diagnostics Market Size by Application (2015-2020)
    • 5.2 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2021-2026)

    6 North America

    • 6.1 North America Companion Cancer Diagnostics Market Size (2015-2020)
    • 6.2 Companion Cancer Diagnostics Key Players in North America (2019-2020)
    • 6.3 North America Companion Cancer Diagnostics Market Size by Type (2015-2020)
    • 6.4 North America Companion Cancer Diagnostics Market Size by Application (2015-2020)

    7 Europe

    • 7.1 Europe Companion Cancer Diagnostics Market Size (2015-2020)
    • 7.2 Companion Cancer Diagnostics Key Players in Europe (2019-2020)
    • 7.3 Europe Companion Cancer Diagnostics Market Size by Type (2015-2020)
    • 7.4 Europe Companion Cancer Diagnostics Market Size by Application (2015-2020)

    8 China

    • 8.1 China Companion Cancer Diagnostics Market Size (2015-2020)
    • 8.2 Companion Cancer Diagnostics Key Players in China (2019-2020)
    • 8.3 China Companion Cancer Diagnostics Market Size by Type (2015-2020)
    • 8.4 China Companion Cancer Diagnostics Market Size by Application (2015-2020)

    9 Japan

    • 9.1 Japan Companion Cancer Diagnostics Market Size (2015-2020)
    • 9.2 Companion Cancer Diagnostics Key Players in Japan (2019-2020)
    • 9.3 Japan Companion Cancer Diagnostics Market Size by Type (2015-2020)
    • 9.4 Japan Companion Cancer Diagnostics Market Size by Application (2015-2020)

    10 Southeast Asia

    • 10.1 Southeast Asia Companion Cancer Diagnostics Market Size (2015-2020)
    • 10.2 Companion Cancer Diagnostics Key Players in Southeast Asia (2019-2020)
    • 10.3 Southeast Asia Companion Cancer Diagnostics Market Size by Type (2015-2020)
    • 10.4 Southeast Asia Companion Cancer Diagnostics Market Size by Application (2015-2020)

    11 India

    • 11.1 India Companion Cancer Diagnostics Market Size (2015-2020)
    • 11.2 Companion Cancer Diagnostics Key Players in India (2019-2020)
    • 11.3 India Companion Cancer Diagnostics Market Size by Type (2015-2020)
    • 11.4 India Companion Cancer Diagnostics Market Size by Application (2015-2020)

    12 Central & South America

    • 12.1 Central & South America Companion Cancer Diagnostics Market Size (2015-2020)
    • 12.2 Companion Cancer Diagnostics Key Players in Central & South America (2019-2020)
    • 12.3 Central & South America Companion Cancer Diagnostics Market Size by Type (2015-2020)
    • 12.4 Central & South America Companion Cancer Diagnostics Market Size by Application (2015-2020)

    13Key Players Profiles

    • 13.1 F. Hoffmann-La Roche
      • 13.1.1 F. Hoffmann-La Roche Company Details
      • 13.1.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue
      • 13.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Introduction
      • 13.1.4 F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2015-2020))
      • 13.1.5 F. Hoffmann-La Roche Recent Development
    • 13.2 Agilent Technologies
      • 13.2.1 Agilent Technologies Company Details
      • 13.2.2 Agilent Technologies Business Overview and Its Total Revenue
      • 13.2.3 Agilent Technologies Companion Cancer Diagnostics Introduction
      • 13.2.4 Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2015-2020)
      • 13.2.5 Agilent Technologies Recent Development
    • 13.3 QIAGEN
      • 13.3.1 QIAGEN Company Details
      • 13.3.2 QIAGEN Business Overview and Its Total Revenue
      • 13.3.3 QIAGEN Companion Cancer Diagnostics Introduction
      • 13.3.4 QIAGEN Revenue in Companion Cancer Diagnostics Business (2015-2020)
      • 13.3.5 QIAGEN Recent Development
    • 13.4 Abbott Laboratories
      • 13.4.1 Abbott Laboratories Company Details
      • 13.4.2 Abbott Laboratories Business Overview and Its Total Revenue
      • 13.4.3 Abbott Laboratories Companion Cancer Diagnostics Introduction
      • 13.4.4 Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2015-2020)
      • 13.4.5 Abbott Laboratories Recent Development
    • 13.5 Almac Group
      • 13.5.1 Almac Group Company Details
      • 13.5.2 Almac Group Business Overview and Its Total Revenue
      • 13.5.3 Almac Group Companion Cancer Diagnostics Introduction
      • 13.5.4 Almac Group Revenue in Companion Cancer Diagnostics Business (2015-2020)
      • 13.5.5 Almac Group Recent Development
    • 13.6 Danaher Corporation
      • 13.6.1 Danaher Corporation Company Details
      • 13.6.2 Danaher Corporation Business Overview and Its Total Revenue
      • 13.6.3 Danaher Corporation Companion Cancer Diagnostics Introduction
      • 13.6.4 Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2015-2020)
      • 13.6.5 Danaher Corporation Recent Development
    • 13.7 bioMérieuxSA
      • 13.7.1 bioMérieuxSA Company Details
      • 13.7.2 bioMérieuxSA Business Overview and Its Total Revenue
      • 13.7.3 bioMérieuxSA Companion Cancer Diagnostics Introduction
      • 13.7.4 bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2015-2020)
      • 13.7.5 bioMérieuxSA Recent Development
    • 13.8 Myriad Genetics
      • 13.8.1 Myriad Genetics Company Details
      • 13.8.2 Myriad Genetics Business Overview and Its Total Revenue
      • 13.8.3 Myriad Genetics Companion Cancer Diagnostics Introduction
      • 13.8.4 Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2015-2020)
      • 13.8.5 Myriad Genetics Recent Development

    14Analyst's Viewpoints/Conclusions

      15Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
        • 15.1.2 Data Source
      • 15.2 Disclaimer

      This report focuses on the global Companion Cancer Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Companion Cancer Diagnostics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      F. Hoffmann-La Roche
      Agilent Technologies
      QIAGEN
      Abbott Laboratories
      Almac Group
      Danaher Corporation
      bioMérieuxSA
      Myriad Genetics

      Market segment by Type, the product can be split into
      Breast Cancer
      Lung Cancer
      Colorectal Cancer
      Melanoma
      Gastric Cancer
      Market segment by Application, split into
      Pharmaceutical & Biopharmaceutical Companies
      Reference Laboratories
      CROs
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Companion Cancer Diagnostics status, future forecast, growth opportunity, key market and key players.
      To present the Companion Cancer Diagnostics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by type, market and key regions.

      In this study, the years considered to estimate the market size of Companion Cancer Diagnostics are as follows:
      History Year: 2015-2019
      Base Year: 2019
      Estimated Year: 2020
      Forecast Year 2020 to 2026
      For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now